Jiangsu Hansoh Pharmaceutical Co., Ltd.

This early-stage study tests a new drug called HS-10504 combined with other treatments in about 400 adults with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find the safest and most effective dose and to see if the combination can shri…

This study tests a new once-weekly injection called HS-20094 against an existing drug, dulaglutide, for people with type 2 diabetes whose blood sugar is not well controlled with metformin alone or metformin plus another diabetes pill. About 546 adults will receive one of the two …

This early-stage study tests the safety and tolerability of a single injection of HS-20136-2 in 38 healthy adults aged 18-65. Participants are randomly assigned to receive either the drug or a placebo, and no one knows who gets which. The study measures side effects and how the d…

This early-stage study will test the safety and tolerability of a single dose of HS-20152, a new drug that targets the complement pathway (part of the immune system), in 32 healthy adults aged 18 to 64. Participants will be randomly assigned to receive either the drug or a placeb…